ARTICLE
28 August 2020

Recent Developments In Patent Law: Non-Obviousness Of Chemical And Pharmaceutical Patents

FH
Finnegan, Henderson, Farabow, Garrett & Dunner, LLP

Contributor

Finnegan, Henderson, Farabow, Garrett & Dunner, LLP is a law firm dedicated to advancing ideas, discoveries, and innovations that drive businesses around the world. From offices in the United States, Europe, and Asia, Finnegan works with leading innovators to protect, advocate, and leverage their most important intellectual property (IP) assets.
Join a discussion on recent developments in patent law, particularly the non-obviousness of chemical and pharmaceutical patents.
United States Intellectual Property
To print this article, all you need is to be registered or login on Mondaq.com.

Join a discussion on recent developments in patent law, particularly the non-obviousness of chemical and pharmaceutical patents. During the interactive webinar, you will be apprised of these developments, which can substantially impact patent protection of chemical and pharmaceutical innovations.

Topics to be discussed include:

  • Chemical and pharmaceutical development is highly complex and uncertain, and various approaches are not "obvious to try"
  • Hindsight reasoning is legally improper and cannot be used to invalidate patent claims
  • Evidence of secondary considerations, such as long-felt unmet need and unexpected results, can support a finding of non-obviousness

Scheduling Conflict? Finnegan records all hosted webinars. To view the recorded program, simply register for the webinar and you will receive an access link shortly after the live program is complete.

Originally published August 20, 2020.

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

See More Popular Content From

Mondaq uses cookies on this website. By using our website you agree to our use of cookies as set out in our Privacy Policy.

Learn More